ub.xmlui.mirage2.page-structure.muninLogoub.xmlui.mirage2.page-structure.openResearchArchiveLogo
    • EnglishEnglish
    • norsknorsk
  • Velg spraaknorsk 
    • EnglishEnglish
    • norsknorsk
  • Administrasjon/UB
Vis innførsel 
  •   Hjem
  • Det helsevitenskapelige fakultet
  • Institutt for klinisk medisin
  • Artikler, rapporter og annet (klinisk medisin)
  • Vis innførsel
  •   Hjem
  • Det helsevitenskapelige fakultet
  • Institutt for klinisk medisin
  • Artikler, rapporter og annet (klinisk medisin)
  • Vis innførsel
JavaScript is disabled for your browser. Some features of this site may not work without it.

Blood Pressure Treatment in Kidney Transplant Recipients - Can We Improve?

Permanent lenke
https://hdl.handle.net/10037/21868
DOI
https://doi.org/10.1097/TXD.0000000000001142
Thumbnail
Åpne
article.pdf (655.9Kb)
Publisert versjon (PDF)
Dato
2021-03-25
Type
Journal article
Tidsskriftartikkel
Peer reviewed

Forfatter
Onsøien, Mari Olsen; Midtvedt, Karsten; Reisæter, Anna Varberg; Aasarød, Knut; Waldum-Grevbo, Bård; Vikse, Bjørn Egil; Eriksen, Bjørn Odvar; Åsberg, Anders
Sammendrag
Background - Hypertension in kidney transplant (KTx) recipients is common, affecting both patient and graft survival. Annual data from the Norwegian Renal Registry reveal that <50% of adult (>18 y) KTx recipients reach target blood pressure (BP) ≤130/80 mm Hg. The aim of this study was to identify the determinants of failure to achieve BP control.

Methods - In conjunction with the 2018 annual data reporting, additional questions were added for recipients with BP >130/80 mm Hg (treating physician´s target BP for each patient, reasons for not achieving target, method of measurement).

Results - Annual forms were received from 98% (3407 of 3486) of KTx recipients, with 1787 (52%) reporting a BP >130/80 mm Hg (“above-target” group). These recipients were older, mostly male, with higher body mass index and serum creatinine levels (P < 0.05) compared with patients with controlled hypertension (“on-target” group). Valid survey answers were available for 84% of the “above-target” group (Survresp) with no significant demographic differences versus nonresponders (Survnonresp). Among Survresp, 32% were under antihypertensive dose titration, whereas dose-limiting side effects were reported in 7%. Target BP was confirmed to 130/80 mm Hg for 60% of Survresp. In recipients for whom the treating physician set target BP >130/80 mm Hg, 51% did not reach these individual targets. The number of antihypertensive drugs was significantly higher in the “above-target” group versus “on-target” group (mean 2.1 ± 1.2 versus 1.8 ± 1.3) and 36% versus 25% used ≥3 antihypertensive drugs (P < 0.05). Automatic attended BP measurement was utilized by 51%.

Conclusions - In KTx recipients, a higher BP target achievement seems possible, potentially in the range of 75%-80%.
Forlag
Lippincott, Williams & Wilkins
Sitering
Onsøien, Midtvedt K, Reisæter AV, Aasarød K, Waldum-Grevbo B, Vikse BE, Eriksen BO, Åsberg A. Blood Pressure Treatment in Kidney Transplant Recipients—Can We Improve?. Transplantation direct. 2021;7(4):e688
Metadata
Vis full innførsel
Samlinger
  • Artikler, rapporter og annet (klinisk medisin) [1974]
Copyright 2021 The Author(s)

Bla

Bla i hele MuninEnheter og samlingerForfatterlisteTittelDatoBla i denne samlingenForfatterlisteTittelDato
Logg inn

Statistikk

Antall visninger
UiT

Munin bygger på DSpace

UiT Norges Arktiske Universitet
Universitetsbiblioteket
uit.no/ub - munin@ub.uit.no

Tilgjengelighetserklæring